U.S. stocks were down on Wednesday as financial stocks fell after JPMorgan and Bank of America hinted at revenue weakness in the current quarter.

JPMorgan (JPM.N) Chief Financial Officer Marianne Lake said the decline stemmed from lower volatility compared with a year ago when the United Kingdom was preparing to vote on Brexit.

Bank of America (BAC.N) Chief Executive Brian Moynihan said second-quarter earnings would be hurt by a drop in trading revenue, lower-than-expected interest rates and the sale or shuttering of certain assets.

“There is a choppy sideways market due to the fact that fundamentals are largely unchanged and expectations of market friendly policies in the U.S. are being pushed to 2018,” said Stephen Wood, chief market strategist, North America, Russell Investments.

Seven of the 11 major SP sectors were lower, with the financial index’s .SPSY 1.3 percent fall leading the decliners.

Financials, which have largely outperformed the broader market on bets of fiscal stimulus and simpler banking regulations under President Trump, are on track to decline 0.7 percent so far this year.

JPMorgan (JPM.N) was down 2 percent on Wednesday. Goldman Sachs (GS.N) fell 3 percent and was the biggest drag on the Dow. Bank of America (BAC.N) was down 2.2 percent.

At 10:40 a.m. EDT, the Dow Jones Industrial Average .DJI was down 46.17 points, or 0.22 percent, at 20,983.3, the SP 500 .SPX was down 5.15 points, or 0.21 percent, at 2,407.76 and the Nasdaq Composite .IXIC was down 27.40 points, or 0.44 percent, at 6,175.79.

The Federal Reserve issues its Beige Book at 2 p.m. ET (1800 GMT), a compendium of anecdotes on the health of the economy, that will likely provide further evidence that the economy continues to strengthen giving the Federal Reserve impetus to raise rate next month.

Traders currently see an 86.6-percent chance of a quarter-point rate hike at the Fed’s June meeting, according to Thomson Reuters data.

Shares of Michael Kors (KORS.N) fell 9.4 percent to $32.88 after the luxury fashion retailer gave a bleak full-year forecast and said it would shut more than 100 full-price retail stores in the next two years.

Mallinckrodt (MNK.N) was down 1.1 percent at $43.12, after sources said the drugmaker is exploring a sale of its generic drug unit, in a deal that could fetch as much as $2 billion.